Corvus Pharmaceuticals, Inc., was incorporated in Delaware on January 27, 2014. The company is a clinical-stage biopharmaceutical company that is developing product candidates for proteins that are critical to immune cell function. Its lead drug candidate, soquelitinib, is designed to inhibit ITK and is currently being evaluated in clinical trials for conditions including T-cell lymphoma and atopic dermatitis. The company's strategy focuses on applying its immunology expertise to multiple disease areas with significant unmet medical needs. 

Expected P&L on Expiry

Key Stats

Pricing Model

About CRVS20260417C16